Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06130345 · ClinicalTrials.gov registry record

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

A clinical trial, sponsored by ModernaTX.

Completed
Registry status
15,196,685
Enrollment target

NCT06130345: Completed study, sponsored by ModernaTX.

NCT06130345 is a clinical trial that has completed, run by ModernaTX. The registered enrollment target is 15,196,685 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06130345 has completed, sponsored by ModernaTX.

COMPLETED
Registry status
15,196,685 participants
Enrollment target

Study Summary

The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.

Interventions

  • BIOLOGICAL SPIKEVAX

Trial Details

FieldValue
Enrollment Target 15,196,685 participants
Start Date 2023-04-14
Est. Completion 2024-08-31
ModernaTX

90 total trials

What the finished NCT06130345 record still lists

NCT06130345 is an observational study that tracks outcomes without assigning an intervention. Its 15,196,685 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 1 intervention - of which SPIKEVAX is the first listed.

NCT06130345 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06130345 about?

NCT06130345 is a clinical study titled "Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran". The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.

What is the current status of trial NCT06130345?

This trial is currently completed. The enrollment target is 15,196,685 participants. The study started on 2023-04-14. Estimated completion is 2024-08-31.

What interventions are being tested in trial NCT06130345?

The interventions under investigation include: SPIKEVAX (BIOLOGICAL).

Who is sponsoring clinical trial NCT06130345?

This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02485847 · 20,000,000 participants

    IRIS Registry: Intelligent Research in Sight Registry

  • NCT05678699 · 10,000,000 participants · NA

    The Effects of Medicaid Policy Interventions on Racial Equity in Severe Maternal Morbidity

  • NCT02693223 · 3,892,063 participants

    Get With the Guidelines-Stroke Registry

  • NCT06803498 · 3,000,000 participants

    Delivery Room Intervention and Evaluation Network

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06130345, the US trial registry maintained by the National Library of Medicine. NCT06130345 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.